Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis

Sodium-glucose co-transporter-2 inhibitors (SGLT-2is) are licenced for initiation for glucose lowering in people with type 2 diabetes (T2DM) with an estimated glomerular filtration rate (eGFR)  ≥ 60 mL/min/1.73m2)...

Source: Cardiovascular Diabetology - June 28, 2021 Category: Cardiology Authors: William Hinton, Michael D. Feher, Neil Munro, Mark Joy and Simon de Lusignan Tags: Original investigation Source Type: research